[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asherman-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asherman-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053326","curendo-cord-blood-uterine-regeneration-endometrium-platelet-rich-plasma-therapy-derived-from-umbilical-cord-blood-for-the-treatment-of-endometrial-pathologies-asherman-syndrome--endometrial-atrophy--thin-endometrium-100053326",false,"NCT07697924","CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome \u002F Endometrial Atrophy \u002F Thin Endometrium)","CURENDO","Inclusion Criteria:\n\n* age between 18 and 48 years at the time of recruitment\n* body mass index (BMI): ≥ 18 kg\u002Fm2 and ≤ 35 kg\u002Fm2\n* endometrial thickness \\\u003C 5 mm despite estrogen administration according to each clinic's routine practice for 10 or more days and\u002For evidence of Asherman syndrome.\n\nExclusion Criteria:\n\n* Active genital infection at the time of recruitment\n* chronic endometritis\n* known endometrial pathology\n* psychiatric disorder that could hinder study follow-up\n* positive results on viral safety testing (HBsAg, HBcAb, HCV, HIV-1, HIV-2, syphilis)\n* presence of any syndrome or condition that, in the opinion of the principal investigator, could pose a risk to the study or to the patient\n* any clinically significant abnormality detected during the recruitment process\n* simultaneous participation in another clinical study that could affect the objectives of the present study, or prior participation in this same study.","FEMALE","18 Years","48 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","In recent years, platelet-rich plasma (PRP) has emerged as a promising alternative for treating endometrial pathologies that affect the endometrial lining. Several studies have tested this therapeutic approach in human patients, but the results are inconclusive. Moreover, in recent years, different investigations have suggested that PRP derived from umbilical cord blood (hUC-PRP) contains a higher concentration of growth factors and other pro-regenerative molecules than PRP obtained from adult peripheral blood. In our previous pilot study conducted in 15 patients with endometrial atrophy\u002FAsherman syndrome\u002Fthin endometrium, preliminary results indicate that hysteroscopic injection of hUC-PRP increases endometrial thickness and improves the endometrial pattern. For this reason, the present study aims to corroborate our previous findings by increasing the number of patients to 35, in prior HRT cycles in these women, to gain a deeper understanding of the effectiveness of this new therapy.",[27],"Asherman Syndrome","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-12-18",{"date":36,"type":21},"2029-12",{"name":38,"class":39},"Fundación IVI","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100465657","early-phase-1-bone-marrow-derived-stem-cells-mobilization-for-treatment-of-abnormal-endometrium-100465657","NCT05343572","Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium","Bone Marrow Derived Stem Cells Mobilization for Treatment of Asherman's Syndrome, Atrophic Endometrium, and Recurrent Implantation Failure","Inclusion Criteria:\n\n* Healthy, non pregnant females\n* ages ≥18 and ≤40 years old at time of enrollment\n* with either AS, AE, or RIF\n\n  1. For AS: surgical history of intrauterine trauma\u002Finfection, hypo\u002Famenorrhea, intra-uterine adhesions\n  2. for AE: US documentation of persistent, \\\u003C6mm endometrial thickness\n  3. for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic\n\nExclusion Criteria:\n\n* Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)\n* Endometriosis (diagnosed by previous surgery,)\n* Diminished ovarian reserve (AMH\\\u003C1ng\u002Fml or follicle stimulating hormone (FSH)\\>10)\n* History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly\n* Submucous or intracavitary fibroid, polyps\n* Currently pregnant\n* Personal history of thrombophilia or sickle cell disease\n* Inability to provide informed consent",true,"40 Years",{"count":51,"type":21},90,[53],"EARLY_PHASE1","This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\\[1,4-phenylenebis-(methylene)\\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).",[27,56,57],"Atrophic Endometrium","Recurrent Implantation Failure",[59],"bone marrow derived stem cells","2025-11-07",{"date":62,"type":32},"2025-11-12",{"date":64,"type":32},"2023-11-01",{"date":66,"type":21},"2027-12",{"name":68,"class":39},"Hugh Taylor",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100605303","safety-and-performance-of-the-semical-adhesion-barrier-gel-for-prevention-of-intra-uterine-adhesion-100605303","NCT07160764","Safety and Performance of the Semical Adhesion Barrier Gel for Prevention of Intra-uterine Adhesion","Evaluation of Performance and Safety of Hyalosem Cross-linked Hyaluronic Acid Adhesion Barrier Gel in Preventing Intra-uterine Adhesion Formation After Operative Hysteroscopy: A Retrospective Study","SEMFERTIL","Inclusion Criteria:\n\n* Female patients aged 18 and over\n* Patients who were treated with operative hysteroscopy for intrauterine pathology (endometrial polips, myomas with uterine cavity deformation, uterine septa, intrauterine adhesion, ovarian cyst, endometrial cyst, etc.)\n* Patients who had undergone operative hysteroscopy at least 30 days and at most 6 months ago\n* Patients who had second-look office hysteroscopy at least once after an operative hysteroscopy\n\nExclusion Criteria:\n\n* Children and adolescents under 18 years of age\n* Having a body weight of more than 100 kg\n* Surgeries complicated by excessive bleeding; estimated blood loss of more than 100 cc\n* Surgeries complicated with uterine perforation\n* Presence of uncontrolled diabetes, coagulation disorders, and other severe chronic disorders\n* Presence of malignant tumor or diagnosis of cancer, presence of uterovaginal prolapse\n* Concomitant peritoneal grafting or tubal implantation\n* Concomitant intrauterine device implantation\n* Patients without second-look hysteroscopy\n\nAccording to the GDPR and clinical investigation legislation, written informed consent is not mandatory in retrospective studies as long as the patient's personal information is censored.",{"count":78,"type":21},80,"OBSERVATIONAL","The aim of this study was to obtain short- and long-term performance and safety data of cross-linked hyaluronic acid-based adhesion barrier gel used to prevent intrauterine adhesion formation.",[82,27,83,84,85],"Intrauterine Abnormalities in Infertility","Intra-uterine Adhesions","Postoperative Adhesion of Uterus","Asherman's Syndrome",[87,88,89,90],"intrauterine abnormalities","asherman's syndrome","intrauterine adhesions","postoperative adhesions","NOT_YET_RECRUITING","2025-09-01",{"date":94,"type":32},"2025-09-08",{"date":96,"type":21},"2025-11-01",{"date":98,"type":21},"2025-12-31",{"name":100,"class":101},"Semikal Technology","INDUSTRY"]